Compared with healthy individuals, incretin-induced insulin secretory responses in type 2 diabetes seem to be reduced more (Fig. 3), with less well-controlled plasma glucose concentrations (indicated by lower baseline HbA1c levels, fewer diabetes medications; ESM Table 2). The gene discussed is GCG; the disease is diabetes mellitus.